RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of ATXI
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Green day on Wednesday for Avenue Therapeutics, Inc.
(Updated on Mar 27, 2024)

Sell candidate since Mar 26, 2024 Gain 1.06% PDF

The Avenue Therapeutics, Inc. stock price gained 1.06% on the last trading day (Wednesday, 27th Mar 2024), rising from $0.151 to $0.153. During the last trading day the stock fluctuated 4.86% from a day low at $0.148 to a day high of $0.155. The price has fallen in 5 of the last 10 days and is down by -9.65% for this period. Volume fell on the last day by -624 thousand shares and in total, 491 thousand shares were bought and sold for approximately $74.93 thousand. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -5.38% during the next 3 months and, with a 90% probability hold a price between $0.104 and $0.308 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

ATXI Signals & Forecast

There are few to no technical positive signals at the moment. The Avenue Therapeutics, Inc. stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. On corrections up, there will be some resistance from the lines at $0.155 and $0.155. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Thursday, January 04, 2024, and so far it has fallen -55.42%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell during the last trading day while the price increased. This causes a divergence and may be considered as an early warning, but it may not be. The very low volume increases the risk and reduces the other technical signals issued.

Support, Risk & Stop-loss for Avenue Therapeutics, Inc. stock

Avenue Therapeutics, Inc. finds support from accumulated volume at $0.150 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day, but be aware of low or falling volume as this increases the risk. During the last day, the stock moved $0.0072 between high and low, or 4.86%. For the last week the stock has had daily average volatility of 7.41%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (ATXI) For The Upcoming Trading Day Of Thursday 28th

For the upcoming trading day on Thursday, 28th we expect Avenue Therapeutics, Inc. to open at $0.152, and during the day (based on 14 day Average True Range), to move between $0.137 and $0.168, which gives a possible trading interval of +/-$0.0155 (+/-10.14%) up or down from last closing price. If Avenue Therapeutics, Inc. takes out the full calculated possible swing range there will be an estimated 20.27% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $0.150 (1.70%) than the resistance at $0.174 (13.83%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Avenue Therapeutics, Inc. stock A Buy?

Avenue Therapeutics, Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -5.143 Strong Sell Candidate Unchanged

Predicted Opening Price for Avenue Therapeutics, Inc. of Thursday, March 28, 2024

Fair opening price March 28, 2024 Current price
$0.152 ( 0.349%) $0.153

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for ATXI

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 0.159 4.37 %
R2 0.157 2.57 %
R1 0.155 1.45 %
Current price: 0.153
Support S1 0.149 -2.15 %
S2 0.148 -3.27 %
S3 0.145 -5.07 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 0.190 24.18 %
R2 0.175 14.61 %
R1 0.174 13.83 %
Current price 0.153
Support S1 0.150 -1.70%
S2 0.136 -10.88%
S3 0.120 -21.36%

FAQ

What is the symbol for Avenue Therapeutics, Inc. Stock and on which exchange is it traded?
The symbol for Avenue Therapeutics, Inc. is ATXI and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Avenue Therapeutics, Inc. Stock?
Avenue Therapeutics, Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

How to buy Avenue Therapeutics, Inc. Stock?
Avenue Therapeutics, Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Avenue Therapeutics, Inc. Stock.

What's the current price of Avenue Therapeutics, Inc. Stock?
As of the end of day on the 2024-03-27, the price of an Avenue Therapeutics, Inc. (ATXI) share was $0.153.

What is the 52-week high and low for Avenue Therapeutics, Inc. Stock?
The 52-week high for Avenue Therapeutics, Inc. Stock is $1.36 and the 52-week low is $0.113.

What is the market capitalization of Avenue Therapeutics, Inc. Stock?
As of the 2024-03-27, the market capitalization of Avenue Therapeutics, Inc. is 6.683M.

When is the next earnings date for Avenue Therapeutics, Inc.?
The upcoming earnings date for Avenue Therapeutics, Inc. is May 10, 2024.
Click to get the best stock tips daily for free!

About Avenue Therapeutics, Inc.

Avenue Therapeutics. Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.... ATXI Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT